West Pharmaceutical Services Forecasts 2023 Adjusted Diluted EPS Range Excluding Consensus Estimate, With Revenue Range Included.
February 17, 2023
Trending News 🌥️
West Pharmaceutical Services ($NYSE:WST) recently announced a 2023 financial outlook that offers an adjustment to their initial consensus of diluted earnings per share (EPS) and revenue. The EPS range outside of the consensus estimate is set at $7.25 to $7.75, while their revenue is estimated to be between $3.7 billion and $3.9 billion. In making their 2022 financial outlook, West Pharmaceutical Services has chosen to exclude the consensus estimate from the figures, allowing for a more accurate forecast based solely on their own calculations. This move looks to provide a more concrete understanding of their current financial situation and to help them plan for the upcoming year.
The announcement of this 2023 financial outlook is an encouraging sign as it shows that West Pharmaceutical Services is continuing to make progress despite the obstacles presented by the pandemic. This outlook provides investors and stakeholders alike with a much clearer picture of the company’s current financial situation, while also giving them an idea of where they can expect the company to be headed in the near future.
Price History
On Thursday, West Pharmaceutical Services stock opened at $312.6 and closed at $319.8, soaring by 14.5% from its previous closing price of 279.2. This upward trend shows the positive media exposure for the company at the time of writing, and is further validated by the company’s recent announcement of a 2023 adjusted diluted EPS range excluding consensus estimate, with revenue range included. West Pharmaceutical Services’ forecast for the year 2023 put their potential growth at the front and center, making them an attractive investment choice for savvy investors. This forecast indicates the company’s commitment to meeting expectations and providing investors with solid returns in the upcoming year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for WST. More…
| Total Revenues | Net Income | Net Margin |
| 2.91k | 630.6 | 21.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for WST. More…
| Operations | Investing | Financing |
| 654 | -270.8 | -290.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for WST. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.32k | 846 | 33.39 |
Key Ratios Snapshot
Some of the financial key ratios for WST are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 17.5% | 40.6% | 25.5% |
| FCF Margin | ROE | ROA |
| 13.3% | 18.9% | 14.0% |
Analysis
As a GoodWhale user, it is our aim to help you make an informed decision about WEST PHARMACEUTICAL SERVICES. After carefully analyzing their financials, we rate this company as a medium risk investment. While there is always some level of risk involved in any financial decision, WEST PHARMACEUTICAL SERVICES’ financials indicate a greater level of risk compared to other companies in the same industry. Our analysis has uncovered two risk warnings in the balance sheet, non-financial. To access this information, you will need to become a registered GoodWhale user. The information we provide you with is designed to guide you in making the best investment decision for your needs. More…
Peers
The company operates in North America, Europe, Asia, and South America. Seikagaku Corp, Shenyang Xingqi Pharmaceutical Co Ltd, and Shenzhen Salubris Pharmaceuticals Co Ltd are all competitors of West Pharmaceutical Services Inc.
– Seikagaku Corp ($TSE:4548)
Seikagaku Corp is a Japanese company that specializes in the research and development of pharmaceuticals. The company has a market cap of 53.35B as of 2022 and a return on equity of 2.38%. Seikagaku Corp’s products include treatments for osteoarthritis, inflammatory diseases, and cancer.
– Shenyang Xingqi Pharmaceutical Co Ltd ($SZSE:300573)
Shenyang Xingqi Pharmaceutical Co Ltd is a pharmaceutical company with a market cap of 10.63B as of 2022. The company has a return on equity of 12.24%. The company’s main products are traditional Chinese medicines and western medicines. The company also has a research and development center which is responsible for the development of new products and the improvement of existing products. The company has a strong marketing network and a good reputation in the industry.
– Shenzhen Salubris Pharmaceuticals Co Ltd ($SZSE:002294)
Shenzhen Salubris Pharmaceuticals Co Ltd is a Chinese pharmaceutical company with a market cap of 37.86B as of 2022. The company’s ROE is 6.05%. Shenzhen Salubris Pharmaceuticals Co Ltd is engaged in the research, development, manufacture and sale of pharmaceutical products. The company’s products include drugs for the treatment of cardiovascular and cerebrovascular diseases, cancer, infections, digestive diseases and other diseases.
Summary
West Pharmaceutical Services is a pharmaceutical company that specializes in the production, design, and delivery of drug delivery and packaging solutions. The company recently provided its financial outlook for 2023 and forecasts a range of adjusted diluted EPS excluding consensus estimates, with revenue range included. At the time of writing, the media has mostly been positive towards West Pharmaceutical Services, and their stock prices have responded accordingly by increasing. Overall, West Pharmaceutical Services is expected to report strong financials in 2023, which is seen as a positive sign for investors looking for potential growth opportunities in the pharmaceutical sector.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
